Losmapimod continues to show promise
Posted on October 31st, 202210/31/22
Steady improvement seen in data from open-label extension study Losmapimod, a drug that is currently in a Phase 3 clinical trial for FSH muscular dystrophy, continues to slow or stop […]
Filed under: FSHD Research